目的：观察孟鲁司特钠对变应性鼻炎患者血清白介素6及12的影响，以探讨其作用机制。方法确诊的变应性鼻炎患者100例，分为常规治疗组及常规治疗加孟鲁司特钠治疗组，每组各50例；另设健康对照组50例。治疗前后分别收集研究对象外周血及鼻腔分泌物，ELISA法测定IL-6、IL-12含量，进行治疗前后及组间比较。结果孟鲁司特钠治疗组患者临床症状显著减轻（P＜0.01），血清IL-6明显降低（P＜0.01)，IL-12显著升高（P＜0.01)，呈负相关关系。结论孟鲁司特钠治疗AR的机制可能是通过降低IL-6并升高IL-12水平而实现的，它们在AR发病机制中有重要作用。%Objective To investigate the effects of Montelukast sodium on levels of IL-6 and IL-12 in serum and nasal secretion of patients with allergic rhinitis (AR) based on a clinical trial. Methods Included in this study were 100 AR patients randomly divided into 2 groups, with cases in one group being treated by routine therapy (RTG) and those in another group being treated by a combined way with routine therapy and Montelukast sodium (CTG), 50 cases in each group. Moreover, 50 healthy persons were taken as normal control group (NCG) given no any treatment. Then, samples of serum and nasal secretion were taken before and after treatment respectively, and the levels of IL-6 and IL-12 in both samples were determined by the procedure of ELISA to evaluate their differences among different groups and changes in the course of therapy. Results Symptoms of AR were significantly relieved among the cases in CTG following the therapy, with the levels of IL-6 in serum and nasal samples decreased and that of IL-12 in both samples elevated obviously when compared with that before treatment and other groups, with significantly statistical significance (P<0.01). There is a positive correlation among these data. Conclusion The therapeutic mechanism of montelukast sodium on allergic rhinitis should be brought about by decreasing the level of IL-6 and increasing the level of IL-12, which suggests that IL-6 and IL-12 are involved in the pathogenesis of AR as very important inflammatory factors.
展开▼
